On September 24, 2024 BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") reported that it has closed the fourth tranche (the "Fourth Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 3,000,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $150,000.00 (Press release, BioVaxys Technology, SEP 24, 2024, View Source [SID1234646846]). Each Unit consists of one common share in the capital of the Company (each, a "Share") and one whole Share purchase warrant (each, a "Warrant"), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until September 23, 2026, being the date that is 24 months from the date of issue.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company intends to use the proceeds of the Private Placement for general working capital purposes, including enabling the Company to fund and advance its business plans in regard to its successful recent acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX immune educating platform technology, developed by the former Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., which was purchased from IMV USA ("IMV") on February 16, 2024.
No finder’s fees were paid in connection with the Fourth Tranche and all securities issued in connection therewith are subject to a statutory hold period under applicable Canadian securities laws expiring January 24, 2025, being the date that is four months and one day from the date of closing of the Fourth Tranche.
The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States.